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Mutations in KDSR Cause Recessive
Progressive Symmetric Erythrokeratoderma
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The discovery of new genetic determinants of inherited skin disorders has been instrumental to the understanding of epidermal function,
differentiation, and renewal. Here, we show that mutations in KDSR (3-ketodihydrosphingosine reductase), encoding an enzyme in the
ceramide synthesis pathway, lead to a previously undescribed recessive Mendelian disorder in the progressive symmetric erythrokerato-
derma spectrum. This disorder is characterized by severe lesions of thick scaly skin on the face and genitals and thickened, red, and scaly
skin on the hands and feet. Although exome sequencing revealed several of the KDSRmutations, we employed genome sequencing to
discover a pathogenic 346 kb inversion inmultiple probands, and cDNA sequencing and a splicing assay established that twomutations,
including a recurrent silent third base change, cause exon skipping. Immunohistochemistry and yeast complementation studies demon-
strated that the mutations cause defects in KDSR function. Systemic isotretinoin therapy has achieved nearly complete resolution in the
two probands in whom it has been applied, consistent with the effects of retinoic acid on alternative pathways for ceramide generation.Mendelian disorders of cornification (MEDOCs) are severe
skin disorders that feature localized or generalized scaling
and redness and can be associated with significant
morbidity andmortality.Genetic investigationhas revealed
MEDOC-causing mutations in over 50 genes; despite
diverse function, they share a common pathobiologic
feature of increased transepidermal water loss. Included
among MEDOCs are progressive symmetric erythrokerato-
derma (PSEK [MIM: 133200], which shows symmetrically
distributed hyperkeratotic and erythematous plaques on
the face, buttocks, and groin and palmoplantar kerato-
derma in about half of affected individuals) and erythroker-
atoderma variabilis (which exhibits similar features in
conjunction with transient patches of erythema). Both dis-
orders display substantial phenotypic heterogeneity, and
cutaneous involvement can vary markedly from localized
to generalized disease, even within kindreds. Previously
described Mendelian forms of erythrokeratoderma are usu-
ally dominant and often result from heterozygosity for a de
novomutation. These include erythrokeratoderma variabi-
lis (MIM: 133200; caused by heterozygosity for a mutation
in GJB3 [MIM: 603324], GJB4 [MIM: 605425], or GJA1
[MIM: 121014], which encode connexins 31, 30.3, and
43, respectively1–3), Vohwinkel syndrome (MIM: 604117;
caused by heterozygosity for a mutation in LOR [MIM:
152445], encoding loricrin4), and a syndrome of erythro-
keratoderma, ichthyosis, and cardiomyopathy (EKC syn-
drome [MIM: 615821], caused by heterozygosity for
a missense mutation in a single domain of DSP [MIM:
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 2017 American Society of Human Genetics.We recruited a large cohort of 750 kindreds with disor-
ders of cornification, including subjects with ichthyosis
and erythrokeratoderma phenotypes. The Yale Human
Investigation Committee approved the study in accor-
dance with institutional and national ethical standards,
and subjects provided verbal and written informed con-
sent. We screened probands for 48 genes in which muta-
tions cause MEDOCs via targeted amplification and
high-throughput sequencing. Subjects without patho-
genic mutations identified in this gene panel make up a
subset that facilitates the discovery of new genetic causes
of MEDOCs, typically via exome sequencing.3,5
In the course of exome sequencing of the MEDOC dis-
covery cohort, two probands described by their referring
physicians as having an unusual keratinization or PSEK-
like disorder (and unaffected parents) were each found to
be compound heterozygous for a deleterious mutation
and a silent mutation in the same gene, KDSR (MIM:
136440; GenBank: NM_002035.2 and NP_002026.1; Ta-
bles S1 and S2 and Figures S1A and S1B). Subject 429 is
heterozygous for the previously unreported mutation
c.164_166delAAG (p.Gln55_Gly56delinsArg), and subject
101 is heterozygous for the previously unreported splice-
site mutation c.2562A>C. Both subjects are heterozy-
gous for the silent mutation c.879G>A (p.Gln293Gln) (mi-
nor allele frequency 0.00003).
The silent mutation shared by both probands is at the
last base of exon 9. Because guanine is highly conserved
at this position,6 we hypothesized that this mutation
might alter splicing. We used skin tissue from subject 42906510, USA; 2Department of Microbiology, Yale University School of Med-
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Figure 1. KDSR Mutations in PSEK Sub-
jects Include Single-Nucleotide Changes
That Affect Splicing and a 346 kb Inversion
That Abolishes Expression
(A) Reverse transcription and amplification
of a portion of KDSR RNA spanning exons
6–10 from a wild-type control sample
produced a band of the expected size
(543 bp, right lane), whereas RNA from
subject 429, a subject heterozygous for a
substitution at the last base of exon 9
(c.879G>A), also produced a smaller band
(441 bp, left lane) in which exon 9 had
been skipped (r.778_879del [p.Gln260_
Gln293del]). Corresponding Sanger se-
quences are shown in Figure S1C.
(B) Reverse transcription and amplification
of a portion of KDSR RNA generated by
a wild-type KDSR construct expressed
in HEK cells produced a single product
including exons 3–5 (450 bp, middle
lane), whereas RNA from a KDSR construct
with the exon 4 splice acceptor muta-
tion found in subject 101 (c.2562A>C)
produced a smaller band (384 bp, left lane) in which exon 4 had been skipped (r.256_321del [p.Val86_Gln107del]). Corresponding
Sanger sequences are shown in Figure S1D.
(C) When the same experiment shown in (A) was performed with RNA from subject 1107, who, like subject 429, is heterozygous for the
KDSR c.879G>A mutation (causing skipping of exon 9), all amplification products lacked exon 9, demonstrating that his other KDSR
allele harbors a mutation that either also affects exon 9 splicing or ablates expression of KDSR entirely.
(D) Genome sequencing of DNA from subject 1107 revealed a 346 kb inversion on chromosome 18 (g.63,361,789_63,707,612inv),
which flips the genomic sequence between intron 2 of KDSR and intron 1 of SERPINB11, as shown. KDSR is in purple, and SERPINB11
is in green; there are six additional genes between these (not shown). Amplification of genomic DNA across the boundaries of the inver-
sion with the red or blue primer set (arrows) should produce a product only when the inversion is present.
(E) Amplification of genomic DNAwith primers shown in blue in (D) produced the expected PCR product (533 bp) with DNA from sub-
ject 1107 and his mother and with DNA from subject 438 and her father, confirming that both probands are compound heterozygous for
this inversion and another deleterious KDSRmutation (one inherited from each parent). The same result was obtained with the primers
shown in red in (D) (665 bp, not shown). Corresponding Sanger sequences for both primer sets are shown in Figures S1E and S1F.to examine KDSR transcripts, which revealed an in-frame
deletion of exon 9, leading to p.Gln260_Gln293del (Fig-
ures 1A and S1C). Using a splicing assay, we also found
that c.2562A>C results in an in-frame deletion of exon
4, leading to p.Val86_Gln107del (Figures 1B and S1D).
Ongoing exome sequencing of subjects new to our
MEDOC cohort subsequently revealed two probands,
each born to unaffected parents, with single inherited
KDSR mutations (Tables S1 and S2). Subject 1107 is
heterozygous for the mutation shown to result in
p.Gln260_Gln293del, and subject 438 is heterozygous
for the previously unreported mutation c.557A>T
(p.Tyr186Phe). Although exome sequencing did not show
anyotherKDSRmutations in these twoprobands, examina-
tion of aligned reads with the Integrative Genomics Viewer
(IGV)7 revealed that an intronic SNP (c.108þ166C>T,
rs62098681, minor allele frequency 0.01) was most likely
present in both subjects, despite low exome coverage. In
both kindreds, this SNP was inherited from the parent in
whom exome sequencing did not reveal a damaging KDSR
mutation (Tables S2 and S3). Because the minor allele fre-
quency is too high to be plausibly pathogenic for this disor-
der but also too infrequent for this to be a coincidental
observation, we hypothesized that the SNP was a marker
for another KDSRmutation that is shared by both subjects
but is not observable by exome sequencing.The AmeTo investigate the possibility of an intronic mutation
affecting KDSR, we obtained a skin biopsy from subject
1107 to examine KDSR transcripts. Although subject
1107 is heterozygous for the mutation that causes exon 9
skipping, exon 9 was omitted in all KDSR transcripts
detectable in this experiment (Figure 1C). This result indi-
cated that the other allele harbored either an intronic
mutation also affecting splicing of exon 9 or a mutation
that abolishes production of KDSR transcripts altogether.
Sequencing of the entire intronic sequence flanking exon
9 revealed no rare or novel mutations, effectively ruling
out the former possibility.
Subsequent genome sequencing of subject 1107 revealed
a novel 346 kb inversion on chromosome 18
(g.63,361,789_63,707,612inv), which flips the genomic
sequence flanked by intron 2 of KDSR (coded on the ()
strand) and intron 1 of SERPINB11 (a gene distal to KDSR
and coded on the (þ) strand) (Figures 1D and S2). This
inversion replaces KDSR’s upstream promoter and
5,485 bp of gene sequence, including the 50 UTR, start
codon, and first two exons, with unrelated sequence.
PCR with primers at the flanking boundaries confirmed
the presence of this inversion in both subjects 1107 and
438. Similar amplification of parental DNAs affirmed that
in both kindreds this previously unreported mutation is
on the same allele as SNP rs62098681 (as predicted) andrican Journal of Human Genetics 100, 978–984, June 1, 2017 979
Table 1. Compound Heterozygosity for Damaging KDSR Mutations in PSEK Subjects
DNA Change Exon(s) Protein Change Method(s)
Subject
429
Subject
101
Subject
1107
Subject
438
g.63,361,789_63,707,612inv 1, 2 expression lost genome sequencing,
cDNA analysis
– – maternal paternal
c.164_166delAAG 2 p.Gln55_Gly56delinsArg exome sequencing paternal – – –
c.2562A>C 4 p.Val86_Gln107del exome sequencing,
splicing assay
– maternal – –
c.557A>T 6 p.Tyr186Phe exome sequencing – – – maternal
c.879G>A 9 p.Gln293Gln,
p.Gln260_Gln293del
exome sequencing,
cDNA analysis
maternal paternal paternal –
Shown for each mutation are the DNA change, affected exon(s), effect on the protein, method(s) of discovery, and inheritance in subjects (on the maternal or
paternal allele). The genomic position is from the UCSC Genome Browser build hg38. Accession numbers for cDNA, protein, and exon positions are GenBank:
NM_002035.2, NP_002026.1, and NG_028249.1, respectively.consequently that both subjects 1107 and 438 are com-
pound heterozygous for deleterious KDSR mutations (Fig-
ures 1E, S1E, and S1F). The inversion abolishes expression
of KDSR (Figures 1C and 1D). Although fusion transcripts
of KDSR and SERPINB11 are theoretically possible, the
consistent phenotype of subjects with and without the
inversion strongly suggests that such transcripts do not
significantly contribute to the phenotype and that disease
pathobiology results from KDSR loss of function.
All four of the probands compound heterozygous for
deleterious codingmutations in KDSR (Table 1) were found
to exhibit a similar and previously undescribed skin
phenotype (Figure 2). All presented either at birth or in
the perinatal period with thickened red skin with vernix
(subjects 429 and 101), thickened skin in the diaper area
(subject 1107), or tight red skin with deep fissures and980 The American Journal of Human Genetics 100, 978–984, June 1,collodion membrane (subject 438). Erythema faded in
infancy, and by 4 months all four probands developed
well-demarcated, thickened, scaly skin lesions on the
cheeks and periocular areas and erythema and thickening
of the palms and soles. Most experienced thickened scaly
plaques on the genitals, and subject 438 also had well-
demarcated scaly plaques on the torso, legs, and arms. All
reported exacerbation with cold weather. Subject 438’s
sister, who died of pneumonia at 9 days of age, showed
similar skin findings, consistent with inheritance of a
recessive Mendelian disorder.
KDSR encodes 3-ketodihydrosphingosine reductase
(KDSR), an enzyme in the ceramide synthesis pathway
(Figure 3A). After palmitate and serine are condensed by
serine palmitoyl transferase (SPT), KDSR reduces 3-ketodi-
hydrosphingosine (KDS) to dihydrosphingosine (DHS),Figure 2. Clinical and Histologic PSEK
Features Due to KDSR Mutations
The face, palms, soles, and genitals are the
most severely affected areas in all subjects.
(A) Image of the face of subject 101 shows
well-demarcated pink-red plaques, with
overlying thick yellow-white scale, which
are prominent on the cheeks, central fore-
head, and neck. There are focal, denuded,
red areas that showed no evidence of bacte-
rial superinfection but could be the result
of over-grooming.
(B) Subject 1107 has similar focal plaques
with thick scale on the nose, cheeks, and
chin.
(C and D) Images of the palm of subject
1107 (C) and sole of subject 101 (D) show
erythematous palmoplantar hyperkeratosis
with peeling scale.
(E) Histology of affected skin from the
buttock of subject 1107 is remarkable for
epidermal thickening (acanthosis), sparse
to absent keratohyalin granules in the gran-
ular layer, and retention of nuclei in the
stratum corneum (arrow). Epidermal layers
are labeled as follows: B, basal layer; S, stra-
tum spinosum; G, granular layer; SC, stra-
tum corneum.
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Figure 3. KDSR Encodes 3-Ketodihydrosphingosine Reductase,
an Enzyme in the Ceramide Synthesis Pathway
(A) The three major metabolic pathways capable of producing ce-
ramides (the de novo, sphingomyelinase, and salvage pathways)
are shown in purple, aqua, and brown, respectively. KDSR (in
red) is critical to the creation of ceramides via de novo synthesis
but is not intrinsic to the other two pathways.
(B) The domain structure of KDSR and the locations of mutations
in PSEK subjects are shown. The TyrXXXLys, Asn, and Ser residues
that form the canonical catalytic triad are in orange, the putative
ThrGlyXXXGlyxGly NAD binding site and Rossman fold are in
light and dark green, respectively, and the putative transmem-
brane domains are in blue. Putative homodimerization and homo-
tetramerization domains are indicated with boxes. Residues that
are substituted or deleted as a result of mutations in PSEK subjects
are in red.and either DHS or its hydroxylated product PHS is acylated
by ceramide synthases (CERS1–CERS6) for the generation
of ceramides.8,9 Ceramides are central to cutaneous barrier
function and are secreted by keratinocytes with cholesterol
and free fatty acids to form ordered lipid lamellae as cells
transition from the stratum granulosum to the stratum
corneum.10 In addition to playing a role in barrier func-
tion, ceramides regulate cutaneous proliferation and differ-
entiation.11 Recessive mutations in CERS3 (MIM: 615276)
cause ichthyosis characterized by encasement in a collo-
dion membrane at birth, which sheds in infancy to reveal
whole-body erythroderma and fine or coarse scaling.12,13
CERS3 mutations have been found to alter the ceramide
content of epidermis and to lead to defects in cutaneous
differentiation.13
The domain structure of KDSR is homologous to that
of other reductase enzymes (Figure 3B). The canonical
TyrXXXLys reductase active site in KDSR is at amino acids
186–190. Conserved Asn and Ser residues at amino acids
145 and 173, respectively, form the canonical catalyticThe Ametriad within a larger hydrophilic domain that extends
from residues 22 to 270. A structurally conserved NAD-
binding Rossman fold (an alpha-beta fold with a central
beta sheet) extends from the putative NAD binding site
ThrGlyXXXGlyXGly at amino acids 38–45 to residue
222. There are predicted homodimer and homotetramer
interfaces at amino acids 208–268 and 98–268, respec-
tively.14 Immunofluorescence studies have shown that
KDSR localizes to the endoplasmic reticulum (ER), and
proteinase K digestion has demonstrated that the
large hydrophilic domain faces the cytosol.14,15 There
are putative transmembrane domains at residues 1–21,
271–291, and 294–314.14
The KDSR variants p.Val86_Gln107del and p.Gln260_
Gln293del most likely have profound effects on protein
structure. Both affect residues within the hydrophilic enzy-
matic domain. The former occurs within the NAD-binding
domain and the homotetramer interface, and the latter is
within both the homodimer and homotetramer interfaces
and would omit one of the putative transmembrane do-
mains, thereby affecting membrane topology at the C-ter-
minal end of the protein. The p.Gln55_Gly56delinsArg
variant alters highly conserved residues within the hydro-
philic enzymatic domain. The p.Tyr186Phe variant affects
the active-site tyrosine, which is completely conserved in
both orthologs and paralogs and is the most conserved res-
idue in reductase proteins (Figures 3B and S3). SIFT16 and
PolyPhen17 predict that p.Tyr186Phe is highly damaging
with scores of 0 and 1, respectively.
To investigate the consequence of KDSR mutations in
the skin, we immunostained affected tissue from subject
1107 with antibodies to KDSR and to keratin 14 (KRT14, a
marker of basal keratinocytes), keratin 10 (KRT10, a marker
of suprabasal keratinocyte differentiation), and filaggrin
(FLG, a marker of terminal differentiation in the granular
layer of the epidermis). KDSR immunostaining intensity
and localization were similar between normal tissue and
affected tissue from this subject (Figures 4A and 4D).
Although programs of epidermal differentiation can be
grossly disrupted in some disorders of keratinization,
including expansion of basal cell markers and loss of differ-
entiation markers,18,19 affected tissue from subject 1107
showed basal distribution of KRT14 and suprabasal distribu-
tionofKRT10, aswas found innormal tissue (Figures 4B, 4C,
4F, and4G).Notably, despitehistologic absenceof a granular
layer (Figure 2E), affected tissue from subject 1107 showed
expansion of filaggrin immunostaining (Figures 4D and
4H). Together, these results suggest a defect in keratinocyte
terminal differentiation. Similar findings have been seen
in tissue fromaffected individualswithwidespread recessive
congenital ichthyosis due to CERS3 mutations, which also
affect ceramide synthesis.12,13
It has been previously shown that expression of wild-
type human KDSR rescues the growth defect in yeast null
for the orthologous TSC10, which otherwise cannot grow
without supplementation with KDSR product DHS or
PHS.14 To demonstrate the effect of the KDSR mutationsrican Journal of Human Genetics 100, 978–984, June 1, 2017 981
Figure 4. Filaggrin Distribution Is Expanded in Affected PSEK Tissue
Tissue from a normal donor and affected tissue from subject 1107 was immunostained with primary antibodies to KDSR, KRT14, KRT10,
and FLG (Santa Cruz Biotechnology sc-366781, sc-53253, sc-53252, and sc-25897, respectively) and corresponding Cy2 (green) or Cy3
(red) secondary antibodies. DAPI was used as a nuclear counterstain (blue).
(A and E) Positive immunostaining for KDSR (green) was observed in all layers of the epidermis in normal (A) and affected (E) tissue.
(B and F) Positive immunostaining for KRT14 (red) was limited to the basal layer of the epidermis in normal (B) and affected (F) tissue.
(C and G) Positive immunostaining for KRT10 (red), a marker of epidermal differentiation, was limited to the suprabasal epidermis in
normal (C) and affected (G) tissue. Normal tissue showed typical autofluorescence of the stratum corneum.
(D and H) Positive immunostaining for FLG (green), a marker of the granular layer of the epidermis, was tightly restricted in normal tis-
sue (D, arrow) but expanded within affected tissue (H, asterisk).observed in our subjects on the function of KDSR, we ex-
pressed both wild-type and mutant forms of human
KDSR, including all of the mutant forms found in our
initial two subjects, in yeast with TSC10 under a galac-
tose-inducible and glucose-repressible conditional pro-
moter. As expected, wild-type KDSR complemented the
depletion of endogenous Tsc10, but the mutant forms of
KDSR failed to complement, demonstrating their detri-
mental effect on KDSR function (Figures 5 and S4). We
did not test the two other mutations identified. The inver-
sion abolishes expression of KDSR, and the active-site
Tyr186 has been characterized in other studies. This site
is crucial to reductase function in both KDSR and paralo-
gous members of the large reductase family of enzymes.
Tyr-to-Phe substitutions at this site in several other reduc-
tases abolish enzymatic activity in vitro.23–25 Additionally,
a temperature-sensitive p.Tyr186Phe KDSR variant ex-
pressed in Tsc10-null yeast failed to complement at
37C.15
In complex organisms, threemajor pathways are capable
of producing ceramides (Figure 3A). The de novo pathway
generates ceramides ‘‘from scratch’’ via smaller building-
block molecules, whereas the other pathways release ce-
ramides via breakdown of larger molecules, either sphingo-
myelin from cell membranes (sphingomyelinase pathway)
or sphingolipids that are converted to sphingosine and
then acylated to form ceramides (salvage pathway).8,9,26
KDSR is critical to the creation of ceramides via de novo
synthesis but is not intrinsic to the other two pathways.982 The American Journal of Human Genetics 100, 978–984, June 1,Two of the probands (subjects 429 and 438) have been
treated with a systemic retinoic acid derivative (isotreti-
noin), which remarkably resulted in nearly complete
resolution of their scale and erythema (Figure S5). A third
subject (1107) has been advised to start systemic isotreti-
noin therapy as a result of this work. Interestingly, retinoic
acid has been shown to increase sphingosine acylation and
to upregulate sphingomyelinase.27–29 These effects serve to
stimulate the ceramide salvage pathway and sphingomye-
linase pathway, which produce ceramides independent of
KDSR (Figure 3A). This suggests that retinoic acid therapy
is effective, at least in part, by compensating for a genetic
defect in the ceramide de novo synthesis pathway via
pharmacologic induction of alternative pathways for cer-
amide generation.
The identification of four unrelated probands compound
heterozygous for previously unreported or extremely rare
damagingmutations inKDSR, all of whomexhibit a unique
skin disorder with well-demarcated symmetric scaling,
erythema, and mild palmoplantar keratoderma, provides
definitive evidence that recessive mutations in KDSR cause
progressive symmetric erythrokeratoderma. This discovery
underscores the central importance of ceramides in epithe-
lial differentiation. The finding that systemic retinoids lead
to nearly complete resolution of the skin findings in two
subjects, most likely in part through activation of the
salvage pathway for ceramide synthesis, provides an impor-
tant therapeutic opportunity. Finally, RNA analysis and
genome sequencing were essential to the detection of2017
Figure 5. Mutant KDSR Does Not Complement Depletion of
Endogenous Yeast TSC10
A yeast strain with galactose-inducible and glucose-repressible
expression of the KDSR ortholog TSC10 was created,20–22 and
depletion of endogenous TSC10 was verified (Figure S4). Ten-fold
serial dilutions of yeast expressing plasmid-borne mutant forms
of KDSR in the presence or absence of endogenous yeast TSC10
showed severe growth defects in the absence of endogenous
TSC10, whereas both yeast TSC10 and wild-type KDSR fully com-
plemented the loss of endogenous yeast TSC10. The empty vector
served as a negative control.pathogenicmutations. Three of the four subjects arehetero-
zygous for a silent third base change, for which cDNA
sequencing was required to establish its damaging effect
on the transcript, and two of the four are heterozygous for
an inversion undetectable by exome sequencing. Conse-
quently, at least one of the mutations in each of the four
subjects would have been undetected by standardmethods
of exome sequencing andfiltering. Thisworkhighlights the
importance of comprehensive genetic evaluation in the
study of severe, rare disorders such as erythrokeratoderma.Supplemental Data
Supplemental Data include five figures and three tables and can be
found with this article online at http://dx.doi.org/10.1016/j.ajhg.
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